0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free AccessIn advanced and refractory cancer patients in whom no MBTR was recommended from TGP/aCGH, WES/RNA-Seq allowed to identify more alterations which may in turn, in a limited fraction of patients, lead to new MBTR.
Armelle Dufresne, Valéry Attignon, Anthony Ferrari, Laurie Tonon, Sandrine Boyault, Séverine Tabone‐Eglinger, Philippe A. Cassier, Olivier Trédan, Nadège Corradini, Armelle Vinceneux, Aurélie Swalduz, Alain Viari, Sylvie Chabaud, David Pérol, Jean Yves Blay, Pierre Saintigny (2024). Added value of whole‐exome and <scp>RNA</scp> sequencing in advanced and refractory cancer patients with no molecular‐based treatment recommendation based on a 90‐gene panel. , 13(7), DOI: https://doi.org/10.1002/cam4.7115.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2024
Authors
16
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1002/cam4.7115
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
